Security key
68062P106
Olema Pharmaceuticals, Inc. - Common Stock (OLMA)
CUSIP: 68062P106
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 68,238,531
- Total 13F value
- $668,036,044
- Share change
- -2,487,156
- Put/Call ratio
- 3.4%
- SEC-reported price per share
- $9.79
- Number of holders
- 124
- Value change
- -$3,229,086
- Number of buys
- 60
- Number of sells
- 51
- Shares outstanding
- 87,946,648
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
124
Top holders
10
OLMA full security history
Ownership snapshot
Full 13F holder table
Olema Pharmaceuticals, Inc. SEC filings
Olema Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of OLMA - Olema Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Paradigm Biocapital Advis...
Disclosed value leader
Paradigm Biocapital Advis...
Comparable rows
15/15
Latest evidence
30 Jun 2025
3/4/5
13D/G
13F
Lead comparable stake: 10%
13D/G row: Paradigm Biocapital Advisors LP
Showing 1-6 of 15 holder rows.
Quick read
Paradigm Biocapital Advisors LP leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Paradigm Biocapital Advisors LP's linked filing trail.
Comparable ownership
Top 5
Paradigm Biocapital Advisors LP
10%
Logos Global Management LP
4.7%
Point72 Asset Management, L.P.
2.3%
Bain Capital Life Sciences Invest...
7.8%
BVF INC/IL
6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP |
3/4/5
13D/G
13F
10%+ Owner · Company
|
10%
from 13D/G
|
$173,767,954
13,407,200 shares
|
— | 01 Aug 2024 |
| Logos Global Management LP |
13D/G
13F
Company
|
4.7%
|
$16,172,730
3,208,875 shares
|
$0 | 18 Mar 2025 |
| Point72 Asset Management, L.P. |
13D/G
|
2.3%
|
$7,781,412
1,543,931 shares
|
$0 | 31 Mar 2025 |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
7.8%
|
$29,155,244
6,843,954 shares
|
— | 30 Jun 2025 |
| BVF INC/IL |
13F
Company
|
6%
|
$22,560,504
5,295,893 shares
|
— | 30 Jun 2025 |
| BlackRock, Inc. |
13F
Company
|
5.2%
|
$19,617,764
4,605,109 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
124
Shares
68,238,531
Rows available
124
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
120
Q3 2025 holders
124
Holder diff
4
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|